Clostridium butyricum CBM588
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Clostridium butyricum CBM588, covering 2025-05-18 to 2025-05-18. Get the full timeline:
Most recent: Clinical Trial Update: Clostridium Butyricum CBM588® vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study [NA]